在肿瘤和自免之后，强势崛起的减重赛道，是对未来若干年全球医药产业格局影响最大的一个变量。 围绕着减重赛道的军备竞赛，已经成为诸多医药巨头优先级最高的研发课题之一，相关的并购与BD交 易也呈现极为活跃的状态。 就在刚刚过去的9月，辉瑞公司以惊人的73亿美元的对价，收购了成立时间仅仅3年多的Biotech公司 Metsera，以获得对方的一揽子减重药物管线。 对于中国创新药公司而言，在过去一年多的时间内，也产生了多起首付款超1亿美元的减重药物管线对 外BD，买主包括诺和诺德、默克、再生元多家大型跨国药企。 但是这或许只是一个序曲，在减重药物这个战略性的赛道，属于中国创新药公司的辉煌篇章，还在酝酿 之中。 安全性更优的ActRII单抗 2025年9月29日，一款来自中国Biotech公司来凯医药（02105）的ActRII单抗LAE102，公布了I期临床 MAD研究数据。 这是一项随机、双盲、安慰剂对照研究，旨在评估皮下给药的LAE102在超重/肥胖受试者中的安全性、 耐受性、药代动力学和药效学特征。 一方面，是在MAD试验中，观察到了LAE102的增肌减脂的趋势：在第5周时，LAE102的6mg/kg剂量组 的受 ...

开源证券发布研报称，小核酸药物布局减重适应症主要围绕INHBE和ALK7两个靶点。从企业布局角度 来看，目前进度最快的是Arrowhead和Wave，INHBE siRNA分子都将在未来6个月内读出1期试验数据。 临床前大鼠数据显示，Arrowhead的ALK7siRNA分子联用Tirzepatide可以进一步提升减重效果的同时， 还有望带来更持久的疗效，从而实现更长间隔的给药(如月度、季度等)。同时，联用还有望实现高质量 减重，即减脂不减肌。 开源证券主要观点如下： 减重赛道新风口：小核酸药物有望破局千亿美金市场 小核酸药物布局减重适应症主要围绕INHBE(Inhibin subunit beta E)和ALK7(Activin receptor-like kinase7) 两个靶点。INHBE主要在肝脏细胞中表达，作为一种抑制性因子，负责编码并分泌Activin E。这一分子 与其他配体(如GDF3,GDF11,ActB,ActE,ActAB,ActC,Nodal)共同作用，通过结合ALK7来调控脂肪代谢。 ALK7主要在脂肪组织中表达，是INHBE发挥作用的受体。当Activin E与ALK7结合后，抑 ...

医药生物 2025 年 09 月 25 日 投资评级：看好（维持） 行业走势图 数据来源：聚源 0% 12% 24% 36% 48% 60% 2024-09 2025-01 2025-05 医药生物 沪深300 相关研究报告 《原料药公司加速创新药布局，AI+ 医疗布局逐步深化—行业深度报告》 -2025.9.24 《集采优化叠加创新驱动，Pharma 迎 来 发 展 新 阶 段 — 行 业 点 评 报 告 》 -2025.9.22 《创新药行业进入快速成长期，关注 未来 6-12 个月投资机会—行业周报》 -2025.9.14 减重赛道全球前沿进展跟踪（三）：新风口之小核酸药物有 减重赛道新风口：小核酸药物有望破局千亿美金市场 小核酸药物布局减重适应症主要围绕 INHBE（Inhibin subunit beta E）和 ALK7 （Activin receptor-like kinase 7）两个靶点。INHBE 主要在肝脏细胞中表达，作为 一种抑制性因子，负责编码并分泌 Activin E。这一分子与其他配体（如 GDF3, GDF11, ActB, ActE, ActAB, ActC, Nodal）共 ...

Market Overview - On September 5, A-shares saw all three major indices rise significantly, with the Shanghai Composite Index up by 1.24%, the Shenzhen Component Index up by 3.89%, and the ChiNext Index up by 6.55% [1] - The total trading volume in the Shanghai and Shenzhen markets was 23,047 billion RMB, showing a significant decrease compared to the previous trading day [2] Sector Performance - The leading sectors included electrical equipment (up 7.19%), telecommunications (up 5.49%), and non-ferrous metals (up 4.39%), while the banking sector experienced a decline of 0.99% [7] - In the new energy sector, the Kexin New Energy ETF (588830) rose by 9.24%, and the ChiNext New Energy ETF (159261) increased by 10.86% [7] Notable Stocks and Indices - The ChiNext 50 index had a daily increase of 7.35% and a year-to-date increase of 43.52% [2] - The North China 50 index rose by 5.15% with a year-to-date increase of 55.92% [2] - The Hang Seng Technology Index increased by 1.95% with a year-to-date increase of 27.29% [6] Investment Insights - Securities firms highlighted the potential in the AI energy industry chain, driven by Nvidia's increased capital expenditure expectations [8] - The lithium battery sector is expected to see advancements in solid-state battery technology, with several automakers planning to achieve mass production by 2026-2027 [8] - The pharmaceutical sector is experiencing a boost due to improved liquidity in Hong Kong stocks, driven by favorable monetary policy and market conditions [9]

Group 1 - The Hang Seng Healthcare Index (HSHCI) increased by 0.37% as of August 4, 2025, with notable gains from companies such as Cloudmed (01952) up 8.70% and Crystal Technology (02228) up 7.19% [3] - The Hang Seng Healthcare ETF (513060) experienced a decline of 0.59%, with a latest price of 0.67 yuan, but showed a 3.36% increase over the past week as of August 1, 2025 [3] - The liquidity of the Hang Seng Healthcare ETF was active, with a turnover rate of 25.84% and a trading volume of 1.911 billion yuan [3] Group 2 - Global advancements in the weight loss sector are gaining attention, with multinational pharmaceutical companies like AbbVie, Roche, and Eli Lilly accelerating their amylin-related pipelines [4] - Eli Lilly's Eloralintide showed promising weight loss results in Phase 1 clinical trials, achieving a maximum weight loss of 11.3% over 12 weeks with a low incidence of gastrointestinal adverse effects [4] - The amylin molecules in development have half-lives ranging from 10 to 18 days, potentially allowing for monthly dosing and improving patient compliance [4] Group 3 - The latest financing buy-in amount for the Hang Seng Healthcare ETF reached 164 million yuan, with a financing balance of 209 million yuan [5] - Over the past two years, the net value of the Hang Seng Healthcare ETF has increased by 28.35%, with a maximum single-month return of 28.34% since inception [5] - The ETF has a Sharpe ratio of 2.39 for the past year, indicating strong risk-adjusted returns [5] Group 4 - The management fee for the Hang Seng Healthcare ETF is 0.50%, and the custody fee is 0.15% [6] - The ETF's tracking error over the past year is 0.060%, the highest tracking precision among comparable funds [6] - The latest P/E ratio for the Hang Seng Healthcare Index is 31.37, indicating it is at a historical low compared to the past three years [6] Group 5 - The top ten weighted stocks in the Hang Seng Healthcare Index account for 62.03% of the index, including companies like BeiGene (06160) and WuXi Biologics (02269) [6]

Investment Rating - The industry investment rating is "Positive" (maintained) [2] Core Insights - The report highlights the significant potential of the amylin market, with major pharmaceutical companies making substantial investments in amylin molecules, indicating a strong growth trajectory [6][9] - Amylin products are showing promising early clinical data in terms of safety and weight loss efficacy, with specific examples demonstrating competitive advantages over existing treatments [7][22] - A dense pipeline of catalysts is expected in the next 6-12 months, with multiple companies set to release critical clinical trial data that could validate the product profiles of amylin candidates [8][29] Summary by Sections Recent Major BD Transactions - AbbVie and Roche have made significant investments in amylin molecules, with AbbVie paying an upfront fee of $350 million and potential milestone payments of up to $1.875 billion for Gubra's amylin molecule [6][17] - Roche has partnered with Zealand to develop petrelintide, with an upfront payment of $1.65 billion and milestone payments reaching $3.6 billion [6][17] Amylin Product Profile - Early data for amylin monotherapy shows excellent safety and weight loss results, with examples like Eli Lilly's Eloralintide demonstrating a maximum weight loss of 11.3% at 12 weeks [7][22] - The report notes that the majority of weight loss from Eloralintide is fat, with preclinical data showing up to 91% of weight loss being fat [23][28] Future Catalysts - A significant number of amylin pipeline data readouts are expected in the next 6-12 months, with major companies like Roche, Eli Lilly, and AstraZeneca anticipated to release phase 2 trial data [8][29] - Companies such as Viking, Structure, and others are also highlighted for their clinical trial progress in the amylin space [8][29] Investment Recommendations - The report recommends focusing on companies like Borui Pharmaceutical and Zhongsheng Pharmaceutical, which are expected to accelerate their presence in the amylin market [9][31] - Beneficiary companies include Viking, Structure, Metsera, and Jiuyuan Gene, which are positioned to gain from advancements in the amylin sector [9][31]

Core Insights - Novo Nordisk's semaglutide has successfully claimed the title of "king of drugs" in Q1 2024, surpassing Merck's Keytruda in sales [2][3] - The success of semaglutide has sparked a research and development frenzy in the global weight loss market among multinational corporations (MNCs) [1][6] - The competitive landscape in the GLP-1 space is intensifying, particularly with Eli Lilly's strong performance and ongoing clinical trials [4][5] Sales Performance - In Q1 2024, Novo Nordisk's semaglutide products generated a total sales revenue of approximately $8.38 billion, with individual products Wegovy, Ozempic, and Rybelsus contributing $2.63 billion, $4.95 billion, and $0.86 billion respectively [2] - Merck's Keytruda reported Q1 sales of $7.2 billion, indicating that semaglutide has overtaken it in sales for the first time [2] Market Dynamics - Novo Nordisk has lowered its full-year performance outlook due to lower-than-expected penetration rates of its GLP-1 products in the U.S. market, despite achieving an 18% sales growth in Q1 [3] - Eli Lilly's GLP-1 products, Mounjaro and Zepbound, generated combined sales of $6.15 billion in Q1, indicating strong competition in the market [4] R&D Developments - Novo Nordisk is focusing on developing new formulations, with the oral version of Wegovy under FDA review, which could become the first oral GLP-1 treatment for long-term weight management if approved [5] - Pfizer has announced a commitment to weight loss drug development but faced setbacks with the termination of its oral GLP-1 drug Danuglipron due to safety concerns [6] CXO Industry Impact - The surge in GLP-1 research has positively impacted domestic CXO companies, with WuXi AppTec's TIDES business achieving a revenue of 5.8 billion yuan in 2023, a 70.1% increase year-on-year [7] - Notable growth has also been reported by Novotech Biopharma, with Q1 revenue of 566 million yuan, a 58.96% increase, and a projected annual revenue growth of nearly 60% for 2024 [7]

Core Viewpoint - Novo Nordisk has made a significant investment of $2 billion to acquire global rights for the development, manufacturing, and commercialization of UBT251 from United Pharmaceuticals, indicating its ambition in the weight loss sector beyond its existing product, semaglutide [1][2][3]. Group 1: Investment and Agreements - Novo Nordisk entered into an exclusive licensing agreement with United Pharmaceuticals, acquiring rights to UBT251, a triple agonist targeting GLP-1, GIP, and glucagon receptors, which is currently in early clinical development [2][3]. - The agreement allows Novo Nordisk to develop and commercialize UBT251 globally, excluding mainland China and certain regions, with United Pharmaceuticals retaining rights in those areas [2][3]. - United Pharmaceuticals is set to receive an upfront payment of $200 million and up to $1.8 billion in potential milestone payments based on development and sales achievements [2][3]. Group 2: Clinical Data and Product Potential - UBT251 has shown superior efficacy in preclinical models for kidney damage compared to semaglutide, particularly in improving markers of renal injury [3][4]. - The drug is being tested for a wide range of indications, including obesity, type 2 diabetes, and chronic kidney disease, with ongoing clinical trials in various populations [3][4]. Group 3: Market Landscape and Competition - The global anti-obesity drug market is projected to reach $100 billion by 2030, attracting numerous competitors [5][6]. - Novo Nordisk's semaglutide has established a leading position in the market, with significant sales figures, while other companies like Eli Lilly and Merck are also developing competing products [5][6][7]. - Recent collaborations by major pharmaceutical companies, such as Roche and AbbVie, indicate a growing interest in long-acting insulin analogs and other innovative treatments for obesity [6][7].